News

SHP621 (budesonide oral suspension) is in phase 3 development for the treatment of eosinophilic esophagitis (EoE). EoE is a severe, chronic and rare disease that stems from an

The facility is scheduled to be operational in September 2016, and will be FDA registered and compliant with Good Manufacturing Practice standards. Spotlight Innovation will also use the

AG-348 is wholly owned by Agios. Data will be presented today at the 21st Congress of the European Hematology Association (EHA) taking place June 9-12, 2016 in Copenhagen.

It is estimated that as many as six million children and adults may be affected by primary immunodeficiencies (PI) worldwide.1 With the addition of Cuvitru following the completion

It has approved the application for dolutegravier 10 milligram and 25 milligram oral tablets, reducing the weight limit to at least 30 kilograms from at least 40 kilograms,

The drugs Dr Reddy’s is acquiring are being sold by Teva to secure US antitrust clearance for its $40.5bn acquisition of Allergan’s generic drugs portfolio. The agreement includes

TD-1473 is specifically designed to penetrate the intestinal wall and act directly at the site of inflammation with minimal systemic exposure. Data from the study demonstrated TD-1473 to

The transaction is conditioned on the close of sufficient financing to fund the operations of the combined company, and due diligence review. FPMI intends to execute the transaction

The sNDA for the 72 mcg dose of linaclotide is based on efficacy and safety data from a double-blind, placebo-controlled Phase III clinical trial of 1,223 adult patients